Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label, Randomized Parallel Controlled Evaluation on the Efficacy and Safety of BDB-001 Injection in the Treatment of Progressive Severe COVID-19 in Phase II/III

Next Previous
Trial Profile

A Multi-center, Open-label, Randomized Parallel Controlled Evaluation on the Efficacy and Safety of BDB-001 Injection in the Treatment of Progressive Severe COVID-19 in Phase II/III

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 24 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BDB 001 Beijing Defengrei Biotechnology (Primary)
  • Indications Acute lung injury; COVID 2019 infections; COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use
  • Sponsors Staidson Beijing BioPharmaceuticals

Most Recent Events

  • 20 May 2024 Status changed from active, no longer recruiting to discontinued.
  • 27 Dec 2023 Planned End Date changed from 7 Aug 2022 to 1 May 2024.
  • 27 Dec 2023 Planned primary completion date changed from 1 Jan 2022 to 1 May 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top